Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Alzheimer's Disease

Interventions

DRUG

ABT-354

ABT-354 Low Dose

DRUG

ABT-354

ABT-354 High Dose

DRUG

Placebo

Trial Locations (3)

Site Reference ID/Investigator# 106998, Orlando

Site Reference ID/Investigator# 106999, Miami

Site Reference ID/Investigator# 107000, Overland Park